Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

701
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
701
Inflammation01:38

Inflammation

46.1K
Overview
46.1K
Angina IV: Management01:26

Angina IV: Management

485
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
485
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

867
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
867

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Steps to Walk Out of, or Side Track, Cardiovascular Disease to Achieve Longevity.

Current vascular pharmacology·2026
Same author

Association of Triglyceride-Glucose Index with Angiographic Thrombus Burden in Patients with ST-Elevation Myocardial Infarction: A Prospective Observational Study.

Journal of clinical medicine·2026
Same author

Sex- and Age-Dependent Outcomes of Cryoablation in Atrial Fibrillation: A 3- and 6-Month Post-Procedural QoL Analysis.

Journal of arrhythmia·2026
Same author

An Individualized Right-to-Left Tunneling "Bail-Out" for Complex ICD Upgrade in a Pacemaker-Dependent Patient: A Case Report and Literature Review.

Journal of personalized medicine·2026
Same author

Mast Cells and Cardiovascular Disorders.

Current vascular pharmacology·2026
Same author

Occupational and Environment-Related Cardiovascular Disease: A Comprehensive Review of the Literature.

Current vascular pharmacology·2026

Related Experiment Video

Updated: Apr 26, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

8.4K

Treating dyslipidemias: is inflammation the missing link?

Nikolaos Papoutsidakis, Spyridon Deftereos, Georgios Giannopoulos

  • 1Department of Cardiology, Athens General Hospital "G. Gennimatas", Mesogeion 154, 11527, Athens, Greece. npapouts2@gmail.com.

Medicinal Chemistry (Shariqah (United Arab Emirates))
|August 8, 2014
PubMed
Summary
This summary is machine-generated.

Low-grade chronic inflammation contributes to atherosclerosis. This review explores how inflammation impacts lipid metabolism, potentially creating a cycle and offering new therapeutic targets for dyslipidemia management.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.7K

Related Experiment Videos

Last Updated: Apr 26, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

8.4K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.7K

Area of Science:

  • Cardiovascular Science
  • Metabolic Research
  • Immunology

Background:

  • Low-grade chronic inflammation is implicated in atherosclerosis development.
  • Emerging evidence links dyslipidemia and inflammation.
  • Inflammation may exacerbate dyslipidemia, forming a detrimental cycle.

Purpose of the Study:

  • To review inflammatory pathways from dyslipidemia to atherogenesis.
  • To examine how inflammation impairs lipid metabolism.
  • To assess the potential of anti-inflammatory therapies in managing dyslipidemia.

Main Methods:

  • Literature review of existing studies.
  • Analysis of inflammatory mechanisms.
  • Evaluation of therapeutic strategies.

Main Results:

  • Dyslipidemia promotes inflammation, contributing to atherosclerosis.
  • Inflammation can negatively alter lipid metabolism.
  • A potential vicious cycle of inflammation and dyslipidemia exists.

Conclusions:

  • Understanding the bidirectional relationship between inflammation and dyslipidemia is crucial.
  • Anti-inflammatory therapies may offer novel approaches for dyslipidemia management.
  • Targeting inflammation presents a promising avenue for preventing atherosclerosis.